Claims

[c1] A preparation for topically delivering and localizing therapeutic agents, comprising:
a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; and
a penetration enhancer for facilitating penetration of said vasoconstrictor and said therapeutic agent through a patient's skin.

[c2] The preparation of **[c1]** , said vasoconstrictor comprising *phenylephrine*.

[c3] The preparation of **[c2]** , wherein:
a clinical concentration of said *phenylephrine* is at least approximately 0.125%; and
said clinical concentration of said *phenylephrine* is at most approximately 1.0%.

[c4] The preparation of **[c3]** , wherein said clinical concentration of said *phenylephrine* is approximately 0.5%.

[c5] The preparation of **[c1]** , said vasoconstrictor comprising a vasoconstrictor selected from the vasoconstrictor group consisting of: *ephedrine sulfate*, *epinephrine*, *naphazoline*, and *oxymetazoline*.

[c6] The preparation of **[c1]** , said penetration enhancer comprising

dimethylsulfoxide.

[c7] The preparation of **[c6]** , wherein a clinical concentration of said *dimethylsulfoxide* is at most approximately 10%.

[c8] The preparation of **[c7]** , wherein said clinical concentration of said *dimethylsulfoxide* is approximately 10%.

[c9] The preparation of **[c1]** , said penetration enhancer comprising *lecithin*.

[c10] The preparation of **[c9]** , said penetration enhancer further comprising *ethoxy diglycol*.

[c11] The preparation of **[c9]** , wherein:
a clinical concentration of said *lecithin* is at least approximately 2%; and
said clinical concentration of said *lecithin* is at most approximately 50%.

[c12] The preparation of **[c11]** , wherein:
said clinical concentration of said *lecithin* is approximately 10% to 12%.

[c13] The preparation of **[c1]** :
said vasoconstrictor comprising *phenylephrine*; and
said penetration enhancer comprising *dimethylsulfoxide*.

[c14] The preparation of **[c13]** , wherein:
a clinical concentration of said *phenylephrine* is at least

approximately 0.125%;

said clinical concentration of said *phenylephrine* is at most approximately 1.0%; and

a clinical concentration of said *dimethylsulfoxide* is at most approximately 10%.

[c15] The preparation of **[c14]** , wherein:

said clinical concentration of said *phenylephrine* is approximately 0.5%; and

said clinical concentration of said *dimethylsulfoxide* is approximately 10%.

[c16] The preparation of **[c13]** , wherein:

a ratio of a clinical concentration of said *dimethylsulfoxide* to a clinical concentration of said *phenylephrine* is at most approximately 40 to 1.

[c17] The preparation of **[c1]** :

said vasoconstrictor comprising *phenylephrine*; and

said penetration enhancer comprising *lecithin*.

[c18] The preparation of **[c17]** , said penetration enhancer further comprising *ethoxy diglycol*.

[c19] The preparation of **[c17]** , wherein:

a clinical concentration of said *phenylephrine* is at least approximately 0.125%;

said clinical concentration of said *phenylephrine* is at most

approximately 1.0%; and

a clinical concentration of said *lecithin* is at most approximately 50%.

[c20] The preparation of **[c19]** , wherein:

said clinical concentration of said *phenylephrine* is approximately 0.5%; and

said clinical concentration of said *lecithin* is approximately 10% to 12%.

[c21] The preparation of **[c17]** , wherein:

a ratio of a clinical concentration of said *lecithin* to a clinical concentration of said *phenylephrine* is at most approximately 200 to 1.

[c22] The preparation of **[c1]** , further comprising:

said therapeutic agent.

[c23] The preparation of **[c22]** , particularly for relieving pain, comprising:

said therapeutic agent comprising a therapeutic pain-relieving agent;

said penetration enhancer for facilitating penetration of said therapeutic pain-relieving agent and said vasoconstrictor through the patient's skin; and

said vasoconstrictor for retarding vascular dispersion of said therapeutic agent.

[c24] The preparation of **[c23]** , said therapeutic pain-relieving agent comprising:
a local anesthetic.

[c25] The preparation of **[c24]** , said local anesthetic comprising *bupivacaine*.

[c26] The preparation of **[c25]** , wherein:
a clinical concentration of said *bupivacaine* is at least approximately 2%; and
said clinical concentration of said *bupivacaine* is at most approximately 10%.

[c27] The preparation of **[c26]** , wherein said clinical concentration of said *bupivacaine* is approximately 5%.

[c28] The preparation of **[c24]** , said local anesthetic comprising a local anesthetic selected from the local anesthetic group consisting of: *mepivacaine*, *levobupivacaine*, *ropivacaine*, *chloroprocaine*, *procaine*, *lidocaine*, *etidocaine*, *benzocaine*, *tetracaine*, and *prilocaine*.

[c29] The preparation of **[c23]** , said therapeutic pain-relieving agent comprising:
a quick-onset, short-acting non-steroidal anti-inflammatory agent.

[c30] The preparation of **[c29]** , said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising *ketoprofen*.

[c31] The preparation of **[c30]** , wherein:
a clinical concentration of said *ketoprofen* is at least approximately 5%; and
said clinical concentration of said *ketoprofen* is at most approximately 20%.

[c32] The preparation of **[c31]** , wherein said clinical concentration of said *ketoprofen* is approximately 10%.

[c33] The preparation of **[c29]** , said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising a quick-onset, short-acting non-steroidal anti-inflammatory agent selected from the quick-onset, short-acting non-steroidal anti-inflammatory agent group consisting of: *diclofenac*, *diflunisal*, *etodolac*, *fenoprofen*, *flurbiprofen*, *ibuprofen*, *indomethacin*, and *tolmetin*.

[c34] The preparation of **[c23]** , said therapeutic pain-relieving agent comprising:
a long-acting non-steroidal anti-inflammatory agent.

[c35] The preparation of **[c34]** , said long-acting non-steroidal anti-inflammatory agent comprising *piroxicam*.

[c36] The preparation of **[c35]** , wherein:
a clinical concentration of said *piroxicam* is at least approximately 0.5%; and
said clinical concentration of said *piroxicam* is at most approximately 4%.

[c37] The preparation of **[c36]** , wherein said clinical concentration of said *piroxicam* is approximately 1.0%.

[c38] The preparation of **[c34]** , said long-acting non-steroidal anti-inflammatory agent comprising a long-acting non-steroidal anti-inflammatory agent selected from the long-acting non-steroidal anti-inflammatory agent group consisting of: *celecoxib*, *meloxicam*, *nabumetone*, *naproxen*, *oxaprozin*, *rofecoxib*, *sulindac*, and *valdecoxib*.

[c39] The preparation of **[c23]** , said therapeutic pain-relieving agent comprising:
a local anesthetic; and
a quick-onset, short-acting non-steroidal anti-inflammatory agent.

[c40] The preparation of **[c39]** :
said local anesthetic comprising *bupivacaine*; and
said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising *ketoprofen*.

[c41] The preparation of **[c23]** , said therapeutic pain-relieving agent comprising:
a local anesthetic; and
a long-acting non-steroidal anti-inflammatory agent.

[c42] The preparation of **[c41]** :
said local anesthetic comprising *bupivacaine*; and
said long-acting non-steroidal anti-inflammatory agent comprising

piroxicam.

[c43] The preparation of **[c23]** , said therapeutic pain-relieving agent comprising:

a quick-onset, short-acting non-steroidal anti-inflammatory agent; and

a long-acting non-steroidal anti-inflammatory agent.

[c44] The preparation of **[c43]** :

said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising *ketoprofen*; and

said long-acting non-steroidal anti-inflammatory agent comprising *piroxicam*.

[c45] The preparation of **[c23]** , said therapeutic pain-relieving agent comprising:

a local anesthetic;

a quick-onset, short-acting non-steroidal anti-inflammatory agent; and

a long-acting non-steroidal anti-inflammatory agent.

[c46] The preparation of **[c45]** :

said local anesthetic comprising *bupivacaine*;

said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising *ketoprofen*; and

said long-acting non-steroidal anti-inflammatory agent comprising *piroxicam*.

[c47] The preparation of **[c46]** , wherein:
a clinical concentration of said *bupivacaine* is at least approximately 2%;
said clinical concentration of said *bupivacaine* is at most approximately 10%;
a clinical concentration of said *ketoprofen* is at least approximately 5%;
said clinical concentration of said *ketoprofen* is at most approximately 20%;
a clinical concentration of said *piroxicam* is at least approximately 0.5%; and
said clinical concentration of said *piroxicam* is at most approximately 4%.

[c48] The preparation of **[c47]** , wherein:
said clinical concentration of said *bupivacaine* is approximately 5%;
said clinical concentration of said *ketoprofen* is approximately 10%; and
said clinical concentration of said *piroxicam* is approximately 1.0%.

[c49] The preparation of **[c22]** , particularly for treating a viral disease, comprising:
said therapeutic agent comprising an antiviral agent;
said penetration enhancer for facilitating penetration of said

antiviral agent and said vasoconstrictor through the patient's skin; and

said vasoconstrictor for retarding vascular dispersion of said antiviral agent.

[c50] The preparation of **[c49]** , said antiviral agent comprising *2-deoxy-d-glucose*.

[c51] The preparation of **[c50]** , wherein:

a clinical concentration of said *2-deoxy-d-glucose* is at least approximately 0.1%; and

said clinical concentration of said *2-deoxy-d-glucose* is at most approximately 0.4%.

[c52] The preparation of **[c51]** , wherein:

said clinical concentration of said *2-deoxy-d-glucose* is approximately 0.2%.

[c53] The preparation of **[c49]** , said antiviral agent comprising an antiviral agent selected from the antiviral agent group consisting of: *podofilox*, *acyclovir*, *penciclovir*, and *docosanol*.

[c54] The preparation of **[c23]** , particularly for relieving pain from a viral disease and treating the viral disease, comprising:

said therapeutic agent further comprising an antiviral agent;

said penetration enhancer for further facilitating penetration of said antiviral agent through the patient's skin; and

said vasoconstrictor for further retarding vascular dispersion of

said antiviral agent.

[c55] The preparation of **[c54]** , said antiviral agent comprising *2-deoxy-d-glucose*.

[c56] The preparation of **[c55]** , wherein:
a clinical concentration of said *2-deoxy-d-glucose* is at least approximately 0.1%; and
said clinical concentration of said *2-deoxy-d-glucose* is at most approximately 0.4%.

[c57] The preparation of **[c56]** , wherein:
said clinical concentration of said *2-deoxy-d-glucose* is approximately 0.2%.

[c58] The preparation of **[c54]** , said antiviral agent comprising an antiviral agent selected from the antiviral agent group consisting of: *podofilox*, *acyclovir*, *penciclovir*, and *docosanol*.

[c59] The preparation of **[c45]** :
said vasoconstrictor comprising *phenylephrine*;
said penetration enhancer comprising a penetration enhancing agent selected from the penetration-enhancing agent group consisting of *dimethylsulfoxide* and *lecithin*;
said local anesthetic comprising *bupivacaine*;
said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising *ketoprofen*; and
said long-acting non-steroidal anti-inflammatory agent comprising

piroxicam.

[c60] The preparation of **[c59]** , wherein:

a clinical concentration of said *phenylephrine* is at least approximately 0.125%;

said clinical concentration of said *phenylephrine* is at most approximately 1.0%;

a clinical concentration of said *dimethylsulfoxide* is at most approximately 10%;

a clinical concentration of said *lecithin* is at most approximately 50%;

a clinical concentration of said *bupivacaine* is at least approximately 2%;

said clinical concentration of said *bupivacaine* is at most approximately 10%;

a clinical concentration of said *ketoprofen* is at least approximately 5%;

said clinical concentration of said *ketoprofen* is at most approximately 20%;

a clinical concentration of said *piroxicam* is at least approximately 0.5%; and

said clinical concentration of said *piroxicam* is at most approximately 4%.

[c61] The preparation of **[c60]** , wherein:

said clinical concentration of said *phenylephrine* is approximately

0.5%;

said clinical concentration of said *bupivacaine* is approximately 5%;

said clinical concentration of said *ketoprofen* is approximately 10%; and

said clinical concentration of said *piroxicam* is approximately 1.0%.

[c62] The preparation of **[c45]** , additionally for treating a viral disease, said therapeutic agent further comprising:

an antiviral agent.

[c63] The preparation of **[c62]** :

said vasoconstrictor comprising *phenylephrine*;

said penetration enhancer comprising a penetration enhancing agent selected from the penetration-enhancing agent group consisting of *dimethylsulfoxide* and *lecithin*;

said local anesthetic comprising *bupivacaine*;

said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising *ketoprofen*;

said long-acting non-steroidal anti-inflammatory agent comprising *piroxicam*; and

said antiviral agent comprising *2-deoxy-d-glucose*.

[c64] The preparation of **[c63]** , wherein:

a clinical concentration of said *phenylephrine* is at least approximately 0.125%;

said clinical concentration of said *phenylephrine* is at most approximately 1.0%;

a clinical concentration of said *dimethylsulfoxide* is at most approximately 10%;

a clinical concentration of said *lecithin* is at most approximately 50%;

a clinical concentration of said *bupivacaine* is at least approximately 2%;

said clinical concentration of said *bupivacaine* is at most approximately 10%;

a clinical concentration of said *ketoprofen* is at least approximately 5%;

said clinical concentration of said *ketoprofen* is at most approximately 20%;

a clinical concentration of said *piroxicam* is at least approximately 0.5%;

said clinical concentration of said *piroxicam* is at most approximately 4%;

a clinical concentration of said *2-deoxy-d-glucose* is at least approximately 0.1%; and

said clinical concentration of said *2-deoxy-d-glucose* is at most approximately 0.4%.

[c65] The preparation of **[c64]** , wherein:

said clinical concentration of said *phenylephrine* is approximately

0.5%;

said clinical concentration of said *bupivacaine* is approximately 5%;

said clinical concentration of said *ketoprofen* is approximately 10%;

said clinical concentration of said *piroxicam* is approximately 1.0%; and

said clinical concentration of said *2-deoxy-d-glucose* is approximately 0.2%.

[c66] A method of topically delivering and localizing therapeutic agents, comprising the steps of:

using a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; in combination with

using a penetration enhancer for facilitating penetration of said vasoconstrictor and said therapeutic agent through a patient's skin.

[c67] The method of **[c66]** , said step of using said vasoconstrictor further comprising the step of using *phenylephrine*.

[c68] The method of **[c67]** , further comprising the steps of:

using a clinical concentration of said *phenylephrine*, of at least approximately 0.125%; and

using said clinical concentration of said *phenylephrine*, of at most approximately 1.0%.

[c69] The method of **[c68]** , further comprising the step of using said clinical concentration of said *phenylephrine*, of approximately 0.5%.

[c70] The method of **[c66]** , said step of using said vasoconstrictor further comprising the step of using a vasoconstrictor selected from the vasoconstrictor group consisting of: *ephedrine sulfate*, *epinephrine*, *naphazoline*, and *oxymetazoline*.

[c71] The method of **[c66]** , said step of using said penetration enhancer further comprising the step of using *dimethylsulfoxide*.

[c72] The method of **[c71]** , further comprising the step of using a clinical concentration of said *dimethylsulfoxide*, of at most approximately 10%.

[c73] The method of **[c72]** , further comprising the step of using said clinical concentration of said *dimethylsulfoxide*, of approximately 10%.

[c74] The method of **[c66]** , said step of using said penetration enhancer further comprising the step of using comprising *lecithin*.

[c75] The method of **[c74]** , said step of using said penetration enhancer further comprising the step of using *ethoxy diglycol*.

[c76] The method of **[c74]** , further comprising the steps of:
using a clinical concentration of said *lecithin*, of at least approximately 2%; and

using said clinical concentration of said *lecithin*, of at most approximately 50%.

[c77] The method of **[c76]** , further comprising the step of:
using said clinical concentration of said *lecithin*, of approximately 10% to 12%.

[c78] The method of **[c66]** :
said step of using said vasoconstrictor further comprising the step of using *phenylephrine*; and
said step of using said penetration enhancer further comprising the step of using *dimethylsulfoxide*.

[c79] The method of **[c78]** , further comprising the steps of:
using a clinical concentration of said *phenylephrine*, of at least approximately 0.125%;
using said clinical concentration of said *phenylephrine*, of at most approximately 1.0%; and
using a clinical concentration of said *dimethylsulfoxide*, of at most approximately 10%.

[c80] The method of **[c79]** , further comprising the steps of:
using said clinical concentration of said *phenylephrine*, of approximately 0.5%; and
using said clinical concentration of said *dimethylsulfoxide*, of approximately 10%.

[c81] The method of **[c78]** , further comprising the step of:

using a ratio of a clinical concentration of said *dimethylsulfoxide* to a clinical concentration of said *phenylephrine*, of at most approximately 40 to 1.

[c82] The method of **[c66]** :
said step of using said vasoconstrictor further comprising the step of using *phenylephrine*; and
said step of using said penetration enhancer further comprising the step of using *lecithin*.

[c83] The method of **[c82]** , said step of using said penetration enhancer further comprising the step of using *ethoxy diglycol*.

[c84] The method of **[c82]** , further comprising the steps of:
using a clinical concentration of said *phenylephrine*, of at least approximately 0.125%;
using said clinical concentration of said *phenylephrine*, of at most approximately 1.0%; and
using a clinical concentration of said *lecithin*, of at most approximately 50%.

[c85] The method of **[c84]** , further comprising the steps of:
using said clinical concentration of said *phenylephrine*, of approximately 0.5%; and
using said clinical concentration of said *lecithin*, of approximately 10% to 12%.

[c86] The method of **[c82]** , further comprising the step of:

using a ratio of a clinical concentration of said *lecithin* to a clinical concentration of said *phenylephrine*, of at most approximately 200 to 1.

[c87] The method of **[c66]** , further comprising the step of:
using said therapeutic agent in combination with using said vasoconstrictor and using said penetration enhancer.

[c88] The method of **[c87]** , particularly for relieving pain:
said step of using said therapeutic agent further comprising the step of using a therapeutic pain-relieving agent; further comprising the steps of:
using said penetration enhancer for facilitating penetration of said therapeutic pain-relieving agent and said vasoconstrictor through the patient's skin; and
using said vasoconstrictor for retarding vascular dispersion of said therapeutic agent.

[c89] The method of **[c88]** , said step of using said therapeutic pain-relieving agent further comprising the step of using a local anesthetic.

[c90] The method of **[c89]** , said step of using said local anesthetic further comprising the step of using *bupivacaine*.

[c91] The method of **[c90]** , further comprising the steps of:
using a clinical concentration of said *bupivacaine*, of at least approximately 2%; and

using said clinical concentration of said *bupivacaine*, of at most approximately 10%.

[c92] The method of **[c91]** , further comprising the step of using said clinical concentration of said *bupivacaine*, of approximately 5%.

[c93] The method of **[c89]** , said step of using said local anesthetic further comprising the step of using a local anesthetic selected from the local anesthetic group consisting of: *mepivacaine*, *levobupivacaine*, *ropivacaine*, *chloroprocaine*, *procaine*, *lidocaine*, *etidocaine*, *benzocaine*, *tetracaine*, and *prilocaine*.

[c94] The method of **[c88]** , said step of using said therapeutic pain-relieving agent further comprising the step of using a quick-onset, short-acting non-steroidal anti-inflammatory agent.

[c95] The method of **[c94]** , said step of using said quick-onset, short-acting non-steroidal anti-inflammatory agent further comprising the step of using *ketoprofen*.

[c96] The method of **[c95]** , further comprising the step of:
using a clinical concentration of said *ketoprofen*, of at least approximately 5%; and
said clinical concentration of said *ketoprofen*, of at most approximately 20%.

[c97] The method of **[c96]** , further comprising the step of using said clinical concentration of said *ketoprofen*, of approximately 10%.

[c98] The method of **[c94]** , said step of using said quick-onset, short-acting non-steroidal anti-inflammatory agent further comprising the step of using a quick-onset, short-acting non-steroidal anti-inflammatory agent selected from the quick-onset, short-acting non-steroidal anti-inflammatory agent group consisting of: *diclofenac*, *diflunisal*, *etodolac*, *fenoprofen*, *flurbiprofen*, *ibuprofen*, *indomethacin*, and *tolmetin*.

[c99] The method of **[c88]** , said step of using said therapeutic pain-relieving agent further comprising the step of using a long-acting non-steroidal anti-inflammatory agent.

[c100] The method of **[c99]** , said step of using said long-acting non-steroidal anti-inflammatory agent further comprising the step of using *piroxicam*.

[c101] The method of **[c100]** , further comprising the steps of:
using a clinical concentration of said *piroxicam*, of at least approximately 0.5%; and
using said clinical concentration of said *piroxicam*, of at most approximately 4%.

[c102] The method of **[c101]** , further comprising the step of using said clinical concentration of said *piroxicam*, of approximately 1.0%.

[c103] The method of **[c99]** , said step of using said long-acting non-steroidal anti-inflammatory agent further comprising the step of using a long-acting non-steroidal anti-inflammatory agent

selected from the long-acting non-steroidal anti-inflammatory agent group consisting of: *celecoxib*, *meloxicam*, *nabumetone*, *naproxen*, *oxaprozin*, *rofecoxib*, *sulindac*, and *valdecoxib*.

[c104] The method of **[c88]** , said step of using said therapeutic pain-relieving agent further comprising the steps of:
using a local anesthetic; and
using a quick-onset, short-acting non-steroidal anti-inflammatory agent.

[c105] The method of **[c104]** :
said step of using said local anesthetic further comprising the step of using *bupivacaine*; and
said step of using said quick-onset, short-acting non-steroidal anti-inflammatory agent further comprising the step of using *ketoprofen*.

[c106] The method of **[c88]** , said step of using said therapeutic pain-relieving agent further comprising the steps of::
using a local anesthetic; and
using a long-acting non-steroidal anti-inflammatory agent.

[c107] The method of **[c106]** :
said step of using said local anesthetic further comprising the step of using *bupivacaine*; and
said step of using said long-acting non-steroidal anti-inflammatory agent further comprising the step of using

piroxicam.

[c108] The method of **[c88]** , said step of using said therapeutic pain-relieving agent further comprising the steps of::

using a quick-onset, short-acting non-steroidal anti-inflammatory agent; and

using a long-acting non-steroidal anti-inflammatory agent.

[c109] The method of **[c108]** :

said step of using said quick-onset, short-acting non-steroidal anti-inflammatory agent further comprising the step of using *ketoprofen*; and

said step of using said long-acting non-steroidal anti-inflammatory agent further comprising the step of using *piroxicam*.

[c110] The method of **[c88]** , said step of using said therapeutic pain-relieving agent further comprising the steps of:

using a local anesthetic;

using a quick-onset, short-acting non-steroidal anti-inflammatory agent; and

using a long-acting non-steroidal anti-inflammatory agent.

[c111] The method of **[c110]** :

said step of using said local anesthetic further comprising the step of using *bupivacaine*;

said step of using said quick-onset, short-acting non-steroidal

anti-inflammatory agent further comprising the step of using *ketoprofen*; and

said step of using said long-acting non-steroidal anti-inflammatory agent further comprising the step of using *piroxicam*.

[c112] The method of **[c111]** , further comprising the steps of:

using a clinical concentration of said *bupivacaine*, of at least approximately 2%;

using said clinical concentration of said *bupivacaine*, of at most approximately 10%;

using a clinical concentration of said *ketoprofen*, of at least approximately 5%;

using said clinical concentration of said *ketoprofen*, of at most approximately 20%;

using a clinical concentration of said *piroxicam*, of at least approximately 0.5%; and

using said clinical concentration of said *piroxicam*, of at most approximately 4%.

[c113] The method of **[c112]** , further comprising the steps of:

using said clinical concentration of said *bupivacaine*, of approximately 5%;

using said clinical concentration of said *ketoprofen*, of approximately 10%; and

using said clinical concentration of said *piroxicam*, of

approximately 1.0%.

[c114] The method of **[c87]** , particularly for treating a viral disease: said step of using said therapeutic agent further comprising the step of using an antiviral agent; further comprising the steps of:
using said penetration enhancer for facilitating penetration of said antiviral agent and said vasoconstrictor through the patient's skin; and
using said vasoconstrictor for retarding vascular dispersion of said antiviral agent.

[c115] The method of **[c114]** , said step of using said antiviral agent further comprising the step of using *2-deoxy-d-glucose*.

[c116] The method of **[c115]** , further comprising the steps of:
using a clinical concentration of said *2-deoxy-d-glucose*, of at least approximately 0.1%; and
using said clinical concentration of said *2-deoxy-d-glucose*, of at most approximately 0.4%.

[c117] The method of **[c116]** , further comprising the step of:
using said clinical concentration of said *2-deoxy-d-glucose*, of approximately 0.2%.

[c118] The method of **[c114]** , said step of using said antiviral agent further comprising the step of using an antiviral agent selected from the antiviral agent group consisting of: *podofilox*, *acyclovir*, *penciclovir*, and *docosanol*.

[c119] The method of **[c88]** , particularly for relieving pain from a viral disease and treating the viral disease:
said step of using said therapeutic agent further comprising the step of using an antiviral agent; further comprising the steps of:
using said penetration enhancer for further facilitating penetration of said antiviral agent through the patient's skin; and
using said vasoconstrictor for further retarding vascular dispersion of said antiviral agent.

[c120] The method of **[c119]** , said step of using said antiviral agent further comprising the step of using *2-deoxy-d-glucose*.

[c121] The method of **[c120]** , further comprising the steps of:
using a clinical concentration of said *2-deoxy-d-glucose*, of at least approximately 0.1%; and
using said clinical concentration of said *2-deoxy-d-glucose*, of at most approximately 0.4%.

[c122] The method of **[c121]** , further comprising the step of:
using said clinical concentration of said *2-deoxy-d-glucose*, of approximately 0.2%.

[c123] The method of **[c119]** , said step of using said antiviral agent further comprising the step of using an antiviral agent selected from the antiviral agent group consisting of: *podofilox*, *acyclovir*, *penciclovir*, and *docosanol*.

[c124] The method of **[c110]** :

said step of using said vasoconstrictor further comprising the step of using *phenylephrine*;

said step of using said penetration enhancer further comprising the step of using a penetration enhancing agent selected from the penetration-enhancing agent group consisting of *dimethylsulfoxide* and *lecithin*;

said step of using said local anesthetic further comprising the step of using *bupivacaine*;

said step of using said quick-onset, short-acting non-steroidal anti-inflammatory agent further comprising the step of using *ketoprofen*; and

said step of using said long-acting non-steroidal anti-inflammatory agent further comprising the step of using *piroxicam*.

[c125] The method of **[c124]** , further comprising the steps of:

using a clinical concentration of said *phenylephrine*, of at least approximately 0.125%;

using said clinical concentration of said *phenylephrine*, of at most approximately 1.0%;

using a clinical concentration of said *dimethylsulfoxide*, of at most approximately 10%;

using a clinical concentration of said *lecithin*, of at most approximately 50%;

using a clinical concentration of said *bupivacaine*, of at least

approximately 2%;

using said clinical concentration of said *bupivacaine*, of at most approximately 10%;

using a clinical concentration of said *ketoprofen*, of at least approximately 5%;

using said clinical concentration of said *ketoprofen*, of at most approximately 20%;

using a clinical concentration of said *piroxicam*, of at least approximately 0.5%; and

using said clinical concentration of said *piroxicam*, of at most approximately 4%.

[c126] The method of **[c125]** , further comprising the steps of:

using said clinical concentration of said *phenylephrine*, of approximately 0.5%;

using said clinical concentration of said *bupivacaine*, of approximately 5%;

using said clinical concentration of said *ketoprofen*, of approximately 10%; and

using said clinical concentration of said *piroxicam*, of approximately 1.0%.

[c127] The method of **[c110]** , additionally for treating a viral disease, said step of using said therapeutic agent further comprising the step of using an antiviral agent.

[c128] The method of **[c127]** :

said step of using said vasoconstrictor further comprising the step of using *phenylephrine*;

said step of using said penetration enhancer further comprising the step of using a penetration enhancing agent selected from the penetration-enhancing agent group consisting of *dimethylsulfoxide* and *lecithin*;

said step of using said local anesthetic further comprising the step of using *bupivacaine*;

said step of using said quick-onset, short-acting non-steroidal anti-inflammatory agent further comprising the step of using *ketoprofen*;

said step of using said long-acting non-steroidal anti-inflammatory agent further comprising the step of using *piroxicam*; and

said step of using said antiviral agent further comprising the step of using *2-deoxy-d-glucose*.

[c129] The method of **[c128]** , further comprising the steps of:

using a clinical concentration of said *phenylephrine*, of at least approximately 0.125%;

using said clinical concentration of said *phenylephrine*, of at most approximately 1.0%;

using a clinical concentration of said *dimethylsulfoxide*, of at most approximately 10%;

using a clinical concentration of said *lecithin*, of at most

approximately 50%;

using a clinical concentration of said *bupivacaine*, of at least approximately 2%;

using said clinical concentration of said *bupivacaine*, of at most approximately 10%;

using a clinical concentration of said *ketoprofen*, of at least approximately 5%;

using said clinical concentration of said *ketoprofen*, of at most approximately 20%;

using a clinical concentration of said *piroxicam*, of at least approximately 0.5%;

using said clinical concentration of said *piroxicam*, of at most approximately 4%;

using a clinical concentration of said *2-deoxy-d-glucose*, of at least approximately 0.1%; and

using said clinical concentration of said *2-deoxy-d-glucose*, of at most approximately 0.4%.

[c130] The method of **[c129]** , further comprising the steps of:

using said clinical concentration of said *phenylephrine*, of approximately 0.5%;

using said clinical concentration of said *bupivacaine*, of approximately 5%;

using said clinical concentration of said *ketoprofen*, of approximately 10%;

using said clinical concentration of said *piroxicam*, of approximately 1.0%; and
using said clinical concentration of said *2-deoxy-d-glucose*, of approximately 0.2%.

[c131] The method of **[c66]** , further comprising the step of:
applying said vasoconstrictor and said penetration enhancer to the patient's skin.

[c132] The method of **[c78]** , further comprising the step of:
applying said *phenylephrine* and said *dimethylsulfoxide* to the patient's skin.

[c133] The method of **[c82]** , further comprising the step of:
applying said *phenylephrine* and said *lecithin* to the patient's skin.

[c134] The method of **[c87]** , further comprising the step of:
applying said vasoconstrictor, said penetration enhancer, and said therapeutic agent to the patient's skin.

[c135] The method of **[c88]** , further comprising the step of:
applying said vasoconstrictor, said penetration enhancer, and said therapeutic pain-relieving agent to the patient's skin.

[c136] The method of **[c89]** , further comprising the step of:
applying said vasoconstrictor, said penetration enhancer, and said local anesthetic to the patient's skin.

[c137] The method of **[c90]** , further comprising the step of:
applying said vasoconstrictor, said penetration enhancer, and said *bupivacaine* to the patient's skin.

[c138] The method of **[c94]** , further comprising the step of:
applying said vasoconstrictor, said penetration enhancer, and said quick-onset, short-acting non-steroidal anti-inflammatory agent to the patient's skin.

[c139] The method of **[c95]** , further comprising the step of:
applying said vasoconstrictor, said penetration enhancer, and said *ketoprofen* to the patient's skin.

[c140] The method of **[c99]** , further comprising the step of:
applying said vasoconstrictor, said penetration enhancer, and said long-acting non-steroidal anti-inflammatory agent to the patient's skin.

[c141] The method of **[c100]** , further comprising the step of:
applying said vasoconstrictor, said penetration enhancer, and said *piroxicam* to the patient's skin.

[c142] The method of **[c110]** , further comprising the step of:
applying said vasoconstrictor, said penetration enhancer, said local anesthetic, said quick-onset, short-acting non-steroidal anti-inflammatory agent, and said long-acting non-steroidal anti-inflammatory agent to the patient's skin.

[c143] The method of **[c111]**, further comprising the step of:
applying said vasoconstrictor, said penetration enhancer, said *bupivacaine*, said *ketoprofen*, and said *piroxicam* to the patient's skin.

[c144] The method of **[c114]** , further comprising the step of:
applying said vasoconstrictor, said penetration enhancer, and said antiviral agent to the patient's skin.

[c145] The method of **[c115]** , further comprising the step of:
applying said vasoconstrictor, said penetration enhancer, and said *2-deoxy-d-glucose* to the patient's skin.

[c146] The method of **[c119]** , further comprising the step of:
applying said vasoconstrictor, said penetration enhancer, therapeutic pain-relieving agent, and said antiviral agent to the patient's skin.

[c147] The method of **[c120]** , further comprising the step of:
applying said vasoconstrictor, said penetration enhancer, therapeutic pain-relieving agent, and said *2-deoxy-d-glucose* to the patient's skin.

[c148] The method of **[c124]**, further comprising the step of:
applying said *phenylephrine*, said penetration enhancing agent selected from the penetration-enhancing agent group consisting of *dimethylsulfoxide* and *lecithin*, said *bupivacaine*, said *ketoprofen*, and said *piroxicam* to the patient's skin.

[c149] The method of **[c127]** , further comprising the step of:
applying said vasoconstrictor, said penetration enhancer, said local anesthetic, said quick-onset, short-acting non-steroidal anti-inflammatory agent, said long-acting non-steroidal anti-inflammatory agent, and said antiviral agent to the patient's skin.

[c150] The method of **[c128]** , further comprising the step of:
applying said *phenylephrine*, said penetration enhancing agent selected from the penetration-enhancing agent group consisting of *dimethylsulfoxide* and *lecithin*, said *bupivacaine*, said *ketoprofen*, said *piroxicam*;, and said *2-deoxy-d-glucose* to the patient's skin.